The IMU platform is being applied across health and disease to advance translational research and accelerate precision drug development.
IMU is at the forefront of accelerating cell therapy drug development processes. Leveraging our advanced immune analytics platform, we address critical development challenges such as donor selection, product characterisation, and patient stratification and monitoring. This integrated approach ensures a more efficient and effective development process to get cutting edge therapies to the right patients.
IMU is dedicated to advancing the field of immuno-oncology by exploring the system-level immune signatures of cancer. Our focus encompasses the entirety of the patient journey, including early detection, precise patient stratification, and advanced monitoring for responses, toxicity, and potential relapse.
IMU is pioneering the use of innovative, systems-level immunological approaches for patient monitoring and the early detection of graft rejection. Our objective is to spearhead the development of the next generation of advanced diagnostic tools, setting new standards in medical technology and patient care.